文献速递类风湿关节炎

单髁与全膝关节置换术后阿片类药物使用、并发症及假体生存:基于人群的网络研究

Opioid use, postoperative complications, and implant survival after unicompartmental versus total knee replacement: a population-based network study.
PubMed 文献 · Lancet Rheumatol · 2019-11-07

该研究基于美英五个医疗数据库,模拟TOPKAT试验设计,比较骨关节炎患者行单髁置换(UKR)与全膝置换(TKR)的术后结局。倾向评分匹配后分析显示,UKR与术后阿片类药物使用和静脉血栓栓塞风险降低相关,但翻修风险增加,感染和再入院无差异,死亡率证据不足。

要点

  • 感染和再入院风险无显著差异,死亡率证据不足。

核心结论

  • UKR与TKR相比,术后阿片类药物使用和静脉血栓栓塞风险降低,但翻修风险增加。

研究设计与样本

  • 基于人群的网络研究,使用美国四个和英国一个医疗数据库(OHDSI网络),模拟TOPKAT试验设计。
  • 纳入年龄≥40岁、因骨关节炎行UKR或TKR且有术前至少一年数据的患者,排除既往膝关节置换、骨折、手术(诊断性除外)、类风湿关节炎、炎性关节病或化脓性关节炎者。

主要发现

  • 死亡率证据不足以得出结论。

关键数值与推荐

  • 阿片类药物使用评估时间窗为术后91-365天。
  • 术后并发症(静脉血栓栓塞、感染、再入院、死亡)评估时间窗为术后60天。
  • 假体生存(翻修)评估时间窗为术后5年。
  • 再入院仅在三个数据库中评估,死亡率仅在两个数据库中评估。

临床怎么用

  • 研究结果可用于符合膝关节置换手术指征患者的共享决策,权衡UKR降低阿片类药物使用和静脉血栓栓塞风险与增加翻修风险之间的利弊。

局限性

  • 观察性研究设计,可能存在未测量混杂。
  • 再入院和死亡率仅在部分数据库中评估。
  • 阿片类药物使用作为持续性疼痛的替代指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is uncertainty around whether to use unicompartmental knee replacement (UKR) or total knee replacement (TKR) for individuals with osteoarthritis confined to a single compartment of the knee. We aimed to emulate the design of the Total or Partial Knee Arthroplasty Trial (TOPKAT) using routinely collected data to assess whether the efficacy results reported in the trial translate into effectiveness in routine practice, and to assess comparative safety. METHODS: We did a population-based network study using data from four US and one UK health-care database, part of the Observational Health Data Sciences and Informatics network. The inclusion criteria were the same as those for TOPKAT; briefly, we identified patients aged at least 40 years with osteoarthritis who had undergone UKR or TKR and who had available data for at least one year prior to surgery. Patients were excluded if they had evidence of previous knee arthroplasty, knee fracture, knee surgery (except diagnostic), rheumatoid arthritis, infammatory arthropathies, or septic arthritis. Opioid use from 91-365 days after surgery, as a proxy for persistent pain, was assessed for all participants in all databases. Postoperative complications (ie, venous thromboembolism, infection, readmission, and mortality) were assessed over the 60 days after surgery and implant survival (as measured by revision procedures) was assessed over the 5 years after surgery. Outcomes were assessed in all databases, except for readmission, which was assessed in three of the databases, and mortality, which was assessed in two of the databases. Propensity score matched Cox proportional hazards models were fitted for each outcome. Calibrated hazard ratios (cHRs) were generated for each database to account for observed differences in control outcomes, and cHRs were then combined using meta-analysis. FINDINGS: 33 867 individuals who received UKR and 557 831 individuals who received TKR between Jan 1, 2005, and April 30, 2018, were eligible for matching. 32 379 with UKR and 250 377 with TKR were propensity score matched and informed the analyses. UKR was associated with a reduced risk of postoperative opioid use (cHR from meta-analysis 0·81, 95% CI 0·73-0·90) and a reduced risk of venous thromboembolism (0·62, 0·36-0·95), whereas no difference was seen for infection (0·85, 0·51-1·37) and readmission (0·79, 0·47-1·25). Evidence was insufficient to conclude whether there was a reduction in risk of mortality. UKR was also associated with an increased risk of revision (1·64, 1·40-1·94). INTERPRETATION: UKR was associated with a reduced risk of postoperative opioid use compared with TKR, which might indicate a reduced risk of persistent pain after surgery. UKR was associated with a lower risk of venous thromboembolism but an increased risk of revision compared with TKR. These findings can help to inform shared decision making for individuals eligible for knee replacement surgery. FUNDING: EU/European Federation of Pharmaceutical Industries and Associations Innovative Medicines Initiative (2) Joint Undertaking (EHDEN).

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Burn E, Weaver J, Morales D, et al. Opioid use, postoperative complications, and implant survival after unicompartmental versus total knee replacement: a population-based network study. Lancet Rheumatol. 2019. PMID: 38229379. doi:10.1016/S2665-9913(19)30075-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。